Abstract:Objective To construct a nanodelivery system surface-modified with RD2 peptide (polypeptide sequence PTLHTHNRRRRR) for brain tissue penetration and β-amyloid (Aβ) binding. Epigallocatechin-3-gallate (EGCG) was selected for encapsulation in the targeted delivery system and its therapeutic potential for Alzheimer's disease (AD) was investigated. Methods EGCG-load nanoparticles (NP/EGCG), NP/EGCG with RD2 peptide surface modification (RD2-NP/EGCG), as well as RD2 peptide-modified blank nanoparticles (RD2-NP) were prepared and characterized. Thioflavin T assay was done to assess the ability of RD2-NP to bind with Aβ and ex vivo imaging was conducted to evaluate the distribution of RD2-NP in brain lesion sites. The AD mice model was established by injecting oligomeric Aβ 42 in the bilateral hippocampi of ICR mice. Then AD mice were administered intravenously through the tail vein with normal saline, EGCG solution, NP/EGCG or RD2-NP/EGCG for 28 d, respectively, and the Morris water maze tests were performed to assess the spatial memory of mice. Subsequently, RT-PCR method was used to determine the mRNA levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the hippocampus of the mice, and the morphological changes of hippocampal neurons were observed with Nissl staining. Additionally, the pathological changes of heart, liver, spleen, lung, and kidney were characterized by hematoxylin-eosin (HE) staining. Results The particle diameter of the prepared RD2-NP/EGCG was (204.83±2.80) nm and the zeta potential was -23.88 mV. The encapsulation efficiency and drug loading capacity were 94.39% and 5.90%, respectively. The RD2 peptide modification has no significant effect on the physiochemical properties of the nanoparticles. RD2-NP had good Aβ binding ability, and it could be concentrated in hippocampus and cerebral cortex, the most common Aβ deposition sites. The four-week RD2-NP/EGCG treatment significantly decreased the expression of the pro-inflammatory cytokine TNF-α and IL-1β, restored neuronal losses and hippocampal damage, and ameliorated spatial memory impairment in AD model mice. Moreover, treatment with the RD2-NP/EGCG did not present organ toxicity. Conclusion Surface modified RD2 peptide nanodelivery system can efficiently deliver drugs to AD lesions and improve the therapeutic effect of EGCG on AD.

Dual-functional Nanoparticles Targeting Amyloid Plaques in the Brains of Alzheimer's Disease Mice

Dual-functional Nanoparticles for Precise Drug Delivery to Alzheimer’s Disease Lesions: Targeting Mechanisms, Pharmacodynamics and Safety

Brain Targeting and Aβ Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice.

[In Vitro Early Detection of Amyloid Plaques in Alzheimer's Disease by Pittsburgh Compound B-modified Magnetic Nanoparticles].

PLGA Nanoparticles Modified with a BBB-penetrating Peptide Co-Delivering Aβ Generation Inhibitor and Curcumin Attenuate Memory Deficits and Neuropathology in Alzheimer's Disease Mice.

The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease.

A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer's disease mice

Brain-neuron Targeted Nanoparticles for Peptide Synergy Therapy at Dual-Target of Alzheimer's Disease.

Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice.

[Constructing Brain Aβ-Targeting Nanoparticles Loaded with EGCG for Treating Alzheimer's Disease in Mice].

Endo/Lysosome‐Escapable Delivery Depot for Improving BBB Transcytosis and Neuron Targeted Therapy of Alzheimer's Disease

A Hybrid Sirna Delivery Complex for Enhanced Brain Penetration and Precise Amyloid Plaque Targeting in Alzheimer's Disease Mice.

Erythrocyte membrane-coated nanocarriers modified by TGN for Alzheimer's disease

A Novel Targeted and High‐Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer’s Disease Therapy

Hybrid Membrane‐Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease

Amyloid-β/Tau Burden and Neuroinflammation Dual-Targeted Nanomedicines Synergistically Restore Memory and Recognition of Alzheimer’s Disease Mice

Rational Design of Dual-Functionalized Gd@C82 Nanoparticles to Relieve Neuronal Cytotoxicity in Alzheimer's Disease Via Inhibition of Aβ Aggregation.

Blood-brain barrier Permeable nanoparticles for Alzheimer's disease treatment by selective mitophagy of microglia

Ultrasound-Excited Protoporphyrin IX-Modified Multifunctional Nanoparticles As a Strong Inhibitor of Tau Phosphorylation and Β-Amyloid Aggregation.

A Dual Targeting Drug Delivery System for Penetrating Blood-Brain Barrier and Selectively Delivering Sirna to Neurons for Alzheimer's Disease Treatment.